Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1103 - Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Hiroki Osumi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

H. Osumi1, E. Shinozaki1, H. Zembutsu2, Y. Takeda3, T. Wakatsuki1, T. Ichimura1, Y. Ota1, I. Nakayama1, M. Ogura1, M. Suenaga1, D. Takahari1, K. Chin1, A. Saiura3, S. Takahashi4, T. Noda2, K. Yamaguchi1

Author affiliations

  • 1 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Cancer Precision Medicine Center, Cancer Institute, Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 3 Department Of Surgery, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 4 Department Of Medical Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1103

Background

Liquid biopsy system using the detection of circulating tumor DNA (ctDNA) is expected to provide the utility as a novel diagnostic tool for cancers.

Methods

We prospectively enrolled a total of 101 metastatic colorectal cancer(mCRC) patients with liver metastasis. We investigated frequency of detectable mutations in cell-free DNA (cfDNA), concordance rate of RAS mutation between tissue and cfDNA, and relationship between the mutant allele frequencies (MAFs) and clinicopathological factors. We further investigated the relationship between time course of ctDNA and chemoresponse. Amplicon-based deep sequencing with molecular barcode (including hotspots of 14 genes) was performed to detect the ctDNA.

Results

Mutation(s) in plasma cfDNA were detected in 87.1% (88/101) of patients. The frequencies of plasma cfDNA mutation at TP53, KRAS, APC, and PIK3CA were 68.3%, 38.6%, 23.7%, and 14.8%, respectively. RAS mutational concordance rate between tissues and cfDNA was 76.2% (77/101). MAFs were significantly associated with CEA (P < 0.0001), CA19-9 (P = 0.006), LDH (P < 0.0001) levels and the number of metastatic organs (P < 0.0001). Patients with liver or lymph node metastasis had significantly higher MAF compared with those without metastases (P < 0.0001, P = 0.008, respectively). The patients with lower MAF at 8 weeks after initiation of chemotherapy showed significantly longer survival than those with higher MAF (>median vs ≤ median, PFS, P = 0.001, OS, P = 0.049). Increase of MAF had been observed earlier than tumor markers before disease progression were confirmed by computed tomography (P = 0.01).

Conclusions

Our results suggested that this cfDNA assay could detect mutations at a high rate of mCRC patients, and could be a useful tool for early detection of chemoresistance as well as a prognostic marker in the clinic.

Clinical trial identification

Legal entity responsible for the study

The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Institutional Review Board.

Funding

Has not received any funding.

Editorial Acknowledgement

Cancer Precision Medicine Center, JFCR: Ms.Aya Imai, Dr. Hiroshi Ohnishi, Mr. Yuki Sano Clinical Examination Center, JFCR: Ms. Kazumi Kaihara and Dr. Konosuke Nakayama University of Chicago: Dr. Yusuke Nakamura.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.